Modality
Nanobody
MOA
PARPi
Target
TIGIT
Pathway
Fibrosis
AS
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Mar 2031
Phase 1Current
NCT03178810
2,526 pts·AS
2021-04→2031-03·Completed
NCT04250895
1,772 pts·AS
2017-08→2030-11·Recruiting
4,298 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-11-094.6y awayPh2 Data· AS
2031-03-255.0y awayPh2 Data· AS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Recruit…
P1/2
Complet…
Catalysts
Ph2 Data
2030-11-09 · 4.6y away
AS
Ph2 Data
2031-03-25 · 5.0y away
AS
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03178810 | Phase 1/2 | AS | Completed | 2526 | MRD |
| NCT04250895 | Phase 1/2 | AS | Recruiting | 1772 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 |